ORCID "0000-0003-4642-3693" Tıp Fakültesi Koleksiyonu için listeleme
-
Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey
Kilickap, S.; Öztürk, A.; Karadurmuş, N.; Korkmaz, T.; Yumuk, P.; Cicin, İrfan; Tunali, D.; Yetişyiğit, Tarkan (Elsevier Science Inc, 2018)[No Abstract Available] -
Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
Kilickap, S.; Demirci, U.; Buğdaycı, F.; Tural, D.; Korkmaz, T.; Paydas, S.; Cicin, İrfan; Seber, Selçuk (Elsevier Science Inc, 2019)[No Abstract Available] -
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
Bilgin, Burak; Sendur, Mehmet Ali; Yücel, Şebnem; Çelik, Emir; Özyükseler, Deniz Tataroğlu; Ayhan, Murat; Yalçın, Bülent; Avcı, Okan (Springer, 2021)Background The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, ...